Segall Bryant & Hamill LLC Increases Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Segall Bryant & Hamill LLC grew its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 97.8% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 80,354 shares of the biopharmaceutical company’s stock after buying an additional 39,721 shares during the period. Segall Bryant & Hamill LLC owned approximately 0.07% of Catalyst Pharmaceuticals worth $1,677,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Rhumbline Advisers boosted its position in shares of Catalyst Pharmaceuticals by 0.3% during the fourth quarter. Rhumbline Advisers now owns 312,320 shares of the biopharmaceutical company’s stock valued at $6,518,000 after buying an additional 952 shares during the last quarter. Handelsbanken Fonder AB lifted its stake in Catalyst Pharmaceuticals by 2.9% during the 4th quarter. Handelsbanken Fonder AB now owns 35,477 shares of the biopharmaceutical company’s stock valued at $740,000 after acquiring an additional 1,000 shares during the period. Xponance Inc. boosted its holdings in shares of Catalyst Pharmaceuticals by 6.8% during the 4th quarter. Xponance Inc. now owns 18,763 shares of the biopharmaceutical company’s stock valued at $392,000 after acquiring an additional 1,189 shares during the last quarter. Steward Partners Investment Advisory LLC bought a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter worth approximately $27,000. Finally, Farther Finance Advisors LLC raised its holdings in shares of Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 1,495 shares during the last quarter. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Down 0.6 %

NASDAQ CPRX opened at $24.69 on Friday. Catalyst Pharmaceuticals, Inc. has a 52 week low of $14.47 and a 52 week high of $26.16. The company has a market capitalization of $3.00 billion, a P/E ratio of 20.92, a price-to-earnings-growth ratio of 3.31 and a beta of 0.84. The stock’s 50-day moving average price is $22.66 and its 200-day moving average price is $21.80.

Insiders Place Their Bets

In other news, insider Gary Ingenito sold 44,904 shares of the stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the sale, the insider now directly owns 68,873 shares of the company’s stock, valued at $1,521,404.57. This represents a 39.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Brian Elsbernd sold 62,975 shares of the firm’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the sale, the insider now owns 188,564 shares in the company, valued at $4,333,200.72. The trade was a 25.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.00% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on CPRX shares. Bank of America reaffirmed a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Stephens reaffirmed an “overweight” rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Baird R W raised Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Monday, February 3rd. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. Finally, HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Catalyst Pharmaceuticals has a consensus rating of “Buy” and an average price target of $32.29.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.